DHEA and Aging: Four Decades of Evidence, Modest Results

Dehydroepiandrosterone (DHEA) is the most abundant adrenal steroid in the human body and the direct precursor to both testosterone and estrogen. It peaks between ages 20–25 and then declines at roughly 2% per year, reaching 10–20% of peak levels by age 70. This dramatic age-related fall — more precipitous than virtually any other hormone in the body — has made DHEA one of the most-studied and most-marketed anti-aging compounds for four decades. The hope was straightforward: restore a declining hormone and restore the youth-associated physiology that goes with it. The reality, as with most attractive anti-aging hypotheses, has proven considerably more complicated.

The Epidemiological Seduction

Observational data established the DHEA-aging story: lower serum DHEAS (the sulfated, circulating storage form) correlates with higher all-cause mortality, greater cardiovascular risk, more pronounced sarcopenia, worse cognitive function, and lower bone density. The biological plausibility was immediate. DHEA and its downstream metabolites regulate immune function, support neurogenesis in the hippocampus, inhibit cortisol-mediated catabolism, and maintain bone mineral density. The epidemiological signal was compelling enough that clinical trials began in earnest in the 1990s.

The critical interpretive question — one that plagues observational hormone data throughout endocrinology — is whether low DHEAS is a cause of aging's consequences or a marker of cumulative physiological deterioration for other reasons. Frail, sick, and inflamed older adults have lower DHEAS partly because inflammation suppresses adrenal steroidogenesis. Correcting the hormone level in someone whose decline reflects underlying morbidity may not address the underlying cause.

What Randomized Trials Have Shown

The most rigorous DHEA supplementation data comes from several placebo-controlled trials in older adults. The DHEA and Well-Ness (DAWN) trial enrolled 110 adults aged 60–88 and gave 50 mg/day of DHEA for 2 years. Results showed no significant improvements in quality of life, physical performance, body composition, cognitive function, or metabolic markers compared to placebo. Bone mineral density showed a marginal, non-significant improvement in women. Serum DHEAS rose substantially, confirming bioavailability — the hormone was absorbed and converted, it just did not produce the expected physiological cascade.

The Mayo Clinic's 2006 RCT in 87 older adults (50 mg/day for 2 years) found modest increases in bone mineral density in women over 70, slight improvements in libido in women, and no significant effects in men on any measured outcome. A 2004 French DHEA trial (DHEAge, n=280, 75 mg/day for 1 year) found improvements in sexual function and skin parameters in women, and modest bone density benefits, but no effects on body composition, cognitive function, or mood. A 2010 Cochrane review of 28 trials concluded that DHEA supplementation produces small benefits in sexual function and bone density in older women, essentially no benefit in men, and no meaningful effects on the broader aging outcomes that motivate most supplementation.

The Cancer Concern

DHEA converts to testosterone and estrogen in peripheral tissues, including in hormone-sensitive tumors. This androgenic and estrogenic activity raises concern about DHEA supplementation in people with or at risk for hormone-sensitive cancers — prostate cancer in men, and breast or endometrial cancer in women. The pharmacological DHEA (Prasterone/Intrarosa, FDA-approved for vulvovaginal atrophy at 6.5 mg/day intravaginally) has a highly localized effect that limits systemic exposure and has not shown increased cancer rates in trials. Oral supplemental DHEA at 25–100 mg/day produces supraphysiological androgen levels in many women (DHEAs often exceeds levels seen at peak youth), raising androgenic side effects (acne, oily skin, facial hair) and theoretical cancer risk. Men supplementing with DHEA can see meaningful increases in estrogen as well as testosterone, an effect that may be unwanted.

Who May Benefit — and at What Dose

The population with the clearest evidence base for DHEA supplementation is women with adrenal insufficiency, where DHEA replacement at 20–50 mg/day consistently improves well-being, sexual function, and mood. For healthy older adults, the data supports only modest benefits in women — primarily bone density and sexual function — and does not support the broad anti-aging claims. If pursuing DHEA supplementation, 25 mg/day is a reasonable starting dose in women (providing a less-than-supraphysiological hormone restoration); 50 mg is the most-studied dose. Serum DHEAS should be tested before starting and again 4–6 weeks later to avoid overshooting. Anyone with a personal or family history of hormone-sensitive cancer should discuss DHEA with their physician before taking it. DHEA is classified as a controlled substance in several countries (Canada, UK, Australia) but is available OTC in the US as a dietary supplement — a regulatory asymmetry that reflects its unusual hormonal activity rather than its safety.